

# Curriculum Vitae

Last Updated: 04/10/2019

## **PERSONAL DATA**

Name: Vanessa Stevens

Citizenship: United States

## **EDUCATION**

<u>Years</u>	<u>Degree</u>	<u>Institution (Area of Study)</u>
2001 - 2004	B.S.	University of Rochester College of Arts and Sciences (Microbiology) Rochester, NY
2004 - 2010	Ph.D.	University of Rochester School of Medicine and Dentistry (Epidemiology) Rochester, NY

## **ACADEMIC HISTORY**

### **Internal Medicine (Epidemiology), 08/16/2016 - Present**

08/16/2016 Hire, Research Track, Research Assistant Professor

### **Pediatrics (Pediatric Infectious Diseases), 09/01/2013 - Present**

09/01/2013 Hire, Adjunct Track, Adjunct Assistant Professor

### **Pharmacotherapy, 09/01/2012 - 08/15/2016**

09/01/2012 Hire, Research Track, Research Assistant Professor

## **PROFESSIONAL EXPERIENCE**

### **Full-Time Positions**

2002 - 2003	Laboratory Research Assistant, Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY
2005 - 2007	Research Assistant, Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY
2008 - 2010	Research Assistant, University of Rochester Center for Community Health, Rochester, NY
2010 - 2012	Postdoctoral Associate, University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Center for Health Outcomes, Pharmacoinformatics, and Epidemiology, Buffalo, NY
2012 - Present	Research WOC, VA Salt Lake City Health Care System, Salt Lake City, UT

### **Reviewer Experience**

Reviewer for Annals of Epidemiology

Reviewer for Biomed Central (BMC) Infectious Diseases

Reviewer for BMJ Open

Reviewer for Clinical and Experimental Gastroenterology

Reviewer for Clinical Infectious Diseases

Reviewer for Clinical Microbiology and Infection

Reviewer for Current Medical Research and Opinion

Reviewer for Diagnostic Microbiology and Infectious Diseases

Reviewer for Expert Review of Anti-Infective Therapy

Reviewer for Health and Quality of Life Outcomes

Reviewer for Infection  
 Reviewer for Infection Control and Hospital Epidemiology  
 Reviewer for JAMA Internal Medicine  
 Reviewer for JAMA Network Open  
 Reviewer for Journal of Pain and Palliative Care Pharmacotherapy  
 Reviewer for Pediatric Blood and Cancer  
 Reviewer for Pharmacoepidemiology and Drug Safety  
 Reviewer for PLoS One

### **SCHOLASTIC HONORS**

2011	Young Investigator Award, for outstanding submitted abstract supporting travel to the congress in Milan, Italy, European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
2011	United University Professionals Professional Development Award, to support educational activities and professional development, United University Professions Buffalo Health Science Center Chapter at the University at Buffalo, Buffalo, NY
2012	Infectious Disease Fellow, 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), American Society of Microbiology, San Francisco, CA
2013 - 2014	Translational Comparative Effectiveness Research Tuition Scholarship Award, University of Utah, Salt Lake City, UT
2013 - 2018	Best Reviewer Award - Pharmacoepidemiology and Drug Safety (Journal)
2013 - 2014	Pediatric Clinical and Translational Research Scholar, University of Utah School of Medicine, Department of Pediatrics, Salt Lake City, UT
2014 - 2016	Vice President's Clinical and Translational (VPCAT) Research Scholar, University of Utah Health Sciences, Salt Lake City, UT
2015	Young Investigator Travel Award, International Conference on Prevention and Infection Control (ICPIC), Geneva, Switzerland
2017	US Department of Veterans Affairs Health Services Research and Development Service Best Research Paper of the Year Award (Nominated)
2018	2018 AAMC Early-Career Women Faculty Leadership Development Seminar Travel Stipend from University of Utah Women in Medicine, Health, and Science
2018	AAMC Early-Career Women Faculty Leadership Development Seminar, Westminster, CO
2018	Top-scoring abstract designation at the European Congress on Clinical Microbiology and Infectious Diseases. Madrid, Spain

### **ADMINISTRATIVE EXPERIENCE**

#### **Professional Organization & Scientific Activities**

2006 - 2007	Program Committee Member, Society for Epidemiologic Research, Student Caucus Executive Committee
2006 - 2010	Committee Member, Society for Epidemiologic Research, Student Caucus Executive Committee
2007 - 2008	President-Elect, Society for Epidemiologic Research, Student Caucus Executive Committee
2008 - 2009	President, Society for Epidemiologic Research, Student Caucus Executive Committee
2009 - 2010	Past President, Society for Epidemiologic Research, Student Caucus Executive Committee

2016 - 2018	Committee Member, Society for Healthcare Epidemiology of America, Antimicrobial Stewardship Research Workshop Planning Committee
<b>Grant Review Committee/Study Section</b>	
2013 - 2018	Ad Hoc Reviewer, Pilot and Small Projects Research Grant Program, Rocky Mountain Center for Occupational and Environmental Health, University of Utah, Salt Lake City, UT
2014	Grant Reviewer, Pharmacist to Treat Program, Utah Department of Health, Salt Lake City, UT
2015 - 2018	Grant Reviewer, Primary Children's Hospital Foundation Early Career Development Award, Salt Lake City, UT

### **PROFESSIONAL COMMUNITY ACTIVITIES**

2017 - Present	Member, U.S. Department of Veterans Affairs, Antimicrobial Stewardship Task Force, Innovation and Development Work Group.
2018 - Present	Chair, U.S. Department of Veterans Affairs, Antimicrobial Stewardship Task Force, Research/Operations Collaboration Work Group

### **UNIVERSITY COMMUNITY ACTIVITIES**

#### **University Level**

2014 - 2015	Member, University Graduate Council
-------------	-------------------------------------

#### **College Level**

2013 - 2016	Member & Mentor, College of Pharmacy, PharmD Mentoring Committee
2014 - 2016	Applicant Interviewer, College of Pharmacy Admissions Committee

#### **Department Level**

2013 - 2016	Committee Member, Pharmacotherapy, Graduate Programs
2013 - 2014	Search Committee, Pharmacotherapy, Tenure and Research Track Faculty Search
2013 - 2015	Coordinator, Pharmacotherapy, Pharmacy Resident Research Training and Mentoring Program
2014	Member, Pharmacotherapy, Clinical Track Faculty Search Committee
2015 - 2016	Director of Graduate Studies, Pharmacotherapy
2019 - Present	Member, Internal Medicine, Mentoring Work Group

#### **Division Level**

2016 - Present	Supervisor, Epidemiology, Antimicrobial Stewardship, Infectious Diseases, and Infection Control (ASIDIC) data group
----------------	---

### **SERVICE AT PREVIOUS INSTITUTIONS**

2005 - 2007	Student Representative, University of Rochester School of Medicine and Dentistry, Department of Community and Preventive Medicine, Graduate Programs Committee
2006 - 2008	Coordinator, University of Rochester School of Medicine and Dentistry, Department of Community and Preventive Medicine, Student-run Epidemiology Journal Club
2010 - 2012	Committee Member, University of Rochester Medical Center, Antimicrobial Stewardship Collaborative

### **CURRENT MEMBERSHIPS IN PROFESSIONAL SOCIETIES**

European Society of Clinical Microbiology and Infectious Diseases  
International Society for Pharmacoepidemiology  
Society for Healthcare Epidemiology of America

## **FUNDING**

### **Active Grants**

- 08/11/15 - 08/10/19 SHEPheRD: Assessment of Patient-Stratified Transmission Risk and Development of Innovative Barrier Precaution Strategies  
Principal Investigator: Matthew H. Samore  
Direct Costs: \$3,099,998 Total Costs: \$3,099,998  
Centers for Disease Control and Prevention  
Role: Co-Investigator
- 09/30/15 - 09/29/19 SHEPheRD: Granular Modeling-Simulating the Transmission of Healthcare Associated Infections in Hospitals and Control Strategies  
Principal Investigator: Matthew H. Samore  
Direct Costs: \$2,222,000 Total Costs: \$2,222,000  
Centers for Disease Control and Prevention  
Role: Co-Investigator
- 07/01/16 - 12/30/19 A comparison of Entresto (valsartan/sacubtril) and angiotensin converting enzyme inhibitor (ABEI) utilization among Veterans with Heart Failure and Reduced Ejection Fraction  
Principal Investigator: Adam Bress  
Direct Costs: \$444,234 Total Costs: \$444,234  
Novartis  
Role: Co-Investigator
- 07/01/17 - 08/31/19 Comparative and Cost Effectiveness of Strategies to Limit MRSA in Long Term Care  
Principal Investigator: Ebbing Lautenbach  
Direct Costs: \$344,629 Total Costs: \$434,233  
Agency for Healthcare Research and Quality  
Role: Principal Investigator (Sub-Contract)
- 10/01/17 - 09/30/19 Early Biothreat Identification using Health Data  
Principal Investigator: Makoto M. Jones  
Direct Costs: \$665,759 Total Costs: \$665,759  
U.S. Department of Homeland Security  
Role: Co-Investigator
- 03/01/18 - 02/28/19 Does prospect theory drive antimicrobial prescription and stewardship decisions?  
Principal Investigator: Richard E. Nelson  
Direct Costs: \$35,000 Total Costs: \$35,000  
University of Utah Department of Internal Medicine  
Role: Co-Investigator
- 08/01/18 - 09/01/19 PCSK9 Inhibitor Initiation among Medicare Beneficiaries and Veterans: A case-crossover study  
Principal Investigator(s): Adam Bress; Paul Muntner  
Direct Costs: \$218,234 Total Costs: \$218,234  
Amgen Inc.  
Role: Co-Investigator
- 10/01/18 - 09/30/19 Correlating the standardized antimicrobial administration ratio with measures of antimicrobial appropriateness and necessity  
Principal Investigator: Vanessa Stevens  
Direct Costs: \$142,800 Total Costs: \$169,932  
Centers for Disease Control and Prevention  
Role: Principal Investigator

10/01/18 - 09/30/23	<p>Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center of Innovation</p> <p>Principal Investigator: Matthew H. Samore</p> <p>Direct Costs: \$3,140,000    Total Costs: \$3,140,000</p> <p>Veterans Affairs Health Services Research &amp; Development</p> <p>Role: <u>Co-Investigator</u> (Methods core lead)</p>
01/01/19 - 12/31/19	<p>Practice variation in the management of skin and soft tissue infections in Veterans</p> <p>Principal Investigator: Jamie W. Rhoads</p> <p>Direct Costs: \$100,000    Total Costs: \$100,000</p> <p>Veterans Affairs Health Services Research &amp; Development</p> <p>Role: <u>Co-Investigator</u></p>
<b>Pending Grants</b>	
04/15/19 - 09/30/20	<p>Antimicrobial Use and Resistance Synthetic Data and New Healthcare-Associated Infection Measure Development</p> <p>Principal Investigator: Makoto M. Jones</p> <p>Direct Costs: \$424,987    Total Costs: \$497,235</p> <p>Centers for Disease Control and Prevention</p> <p>Role: <u>Co-Investigator</u> (<i>Clostridioides difficile</i> project lead)</p>
<b>Past Grants</b>	
11/01/10 - 06/30/12	<p>Occurrence and economic impact of nephrotoxicity associated with vancomycin exposure.</p> <p>Principal Investigator: JE Brown</p> <p>Direct Costs: \$89,051    Total Costs: \$89,051</p> <p>Cubist Pharmaceuticals, Inc.</p> <p>Role: <u>Fellow</u></p>
01/01/14 - 12/31/14	<p>Outcomes of Treatment for <i>Clostridium difficile</i> Infection Among Pediatric Patients</p> <p>Principal Investigator: Vanessa Stevens</p> <p>Direct Costs: \$10,000    Total Costs: \$10,000</p> <p>American Association of Colleges of Pharmacy</p> <p>Role: <u>Principal Investigator</u></p>
01/01/14 - 12/31/16	<p>Molecular Epidemiology of <i>Clostridium difficile</i> in Pediatric Cancer Patients</p> <p>Principal Investigator: Vanessa Stevens</p> <p>Direct Costs: \$50,000    Total Costs: \$50,000</p> <p>Primary Children's Hospital Foundation</p> <p>Role: <u>Principal Investigator</u></p>
06/25/14 - 03/31/16	<p>Prediction of Recurrent <i>Clostridium difficile</i> Infection (CDI) Using Data from the Veterans Health Administration</p> <p>Principal Investigator: Vanessa Stevens</p> <p>Direct Costs: \$156,000    Total Costs: \$207,012</p> <p>Cubist Pharmaceuticals, Inc.</p> <p>Role: <u>Principal Investigator</u></p>
05/01/15 - 12/31/18	<p>Identification of Patients at Risk of <i>Clostridium difficile</i> Infection (CDI) Using Data from the Veterans Health Administration (VHA)</p> <p>Principal Investigator: Matthew H. Samore</p> <p>Direct Costs: \$350,328    Total Costs: \$437,910</p> <p>Pfizer Inc.</p> <p>Role: <u>Co-Investigator</u></p>
06/30/16 - 06/30/17	<p>American Foundation for Pharmaceutical Education Gateway to Research</p>

Fellowship (Trainee Elyse Schwab)  
Principal Investigator(s): Karen M. Gunning; Vanessa Stevens  
Direct Costs: \$5,000 Total Costs: \$5,000  
American Foundation for Pharmaceutical Education  
Role: Principal Investigator

## **TEACHING RESPONSIBILITIES/ASSIGNMENTS**

### **Courses Directed**

2011 - 2012 Director, PM 451: Epidemiology of Infectious Diseases, University of Rochester School of Medicine and Dentistry, Department of Community and Preventive Medicine

### **Course Lectures**

2003 Teaching Assistant, BIO 110: Introduction to Biology, University of Rochester College of Arts and Sciences, Department of Biology

2005 Teaching Assistant, PM 415: Introduction to Epidemiology, University of Rochester School of Medicine and Dentistry, Department of Community and Preventive Medicine

2006 - 2007 Teaching Assistant, PM 416: Advanced Epidemiologic Methods, University of Rochester School of Medicine and Dentistry, Department of Community and Preventive Medicine

2007 Teaching Assistant, PM 429: SAS for Clinicians, University of Rochester School of Medicine and Dentistry, Department of Community and Preventive Medicine

2010 - 2011 Teaching Assistant and Guest Lecturer, PHM 504: Biostatistics in Pharmacy, State University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences

2011 Guest Lecturer, PHM 616: Research Methods in Pharmacy, State University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences

2011 - 2012 Guest Lecturer, State University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice. Preparing Pharmacy Residents for Scholarship

2011 - 2012 Instructor, PM 451: Epidemiology of Infectious Diseases, University of Rochester School of Medicine and Dentistry, Department of Community and Preventive Medicine

2012 - 2016 Guest Lecturer, PCTH 7413 (1): Drug Regimen Clerkship, 6 SCH, 2 students, University of Utah, Pharmacotherapy. *Review and analyses of observational and economic studies (Week 1), Study Design (Week 1)*

2013 - 2016 Guest Lecturer, PCTH 5116 (1): Drug Literature Evaluation I, 186 SCH, 62 students, University of Utah, Pharmacotherapy. *Basic statistics 1 and 2, introduction to epidemiology*

2014 - 2016 Guest Lecturer, PCTH 5125: Drug Literature Evaluation II, 3 credit hours, 60 students, University of Utah, Pharmacotherapy. *Pharmacovigilance, Multivariable Statistics 1 and 2*

2014 Primary Instructor, PCTH 7950 (8): Independent Study, 1 SCH, 1 student, University of Utah, Pharmacotherapy. Infectious Diseases Research

2014 - 2016 Instructor, PCTH 7150 (1): Outcomes Research Elect, 3.0 credit hours, 5 SCH, 2 students, University of Utah, Pharmacotherapy. *Survival Analysis*

2014 - 2016 Faculty Facilitator, PCTH 7200 (1): Clinical Seminar II, 22 SCH, 11 students, University of Utah, Pharmacotherapy

2015 Primary Instructor, PCTH 7950 (12): Independent Study, 1 SCH, 1 student,

2015	University of Utah, Pharmacotherapy. <i>Infectious Diseases Outcomes Research</i> . Primary Instructor, PCTH 7950 (1): Independent Study, 1 SCH, 1 student, University of Utah, Pharmacotherapy. <i>Infectious Diseases Outcomes Research</i> .
2015 - 2017	Primary Instructor, PCTH 7970 (9): Thesis Research, 3 SCH, 1 student, University of Utah, Pharmacotherapy
2016	Primary Instructor, PCTH 7950 (8): Independent Study, 3 SCH, 1 student, University of Utah, Pharmacotherapy. <i>Infectious Diseases Outcomes Research</i> .
2017	Guest Lecturer, FP MD 6308 (1): Biostats Seminar II, 6 SCH, 6 students, University of Utah, Family and Preventive Medicine

### **Small Group Teaching**

2014 - 2016	Pharmacotherapy Seminar, Topic Mentor. University of Utah College of Pharmacy. 2 PharmD Students per semester
-------------	---

### **Trainee Supervision**

#### Fellow

2018 - Present	Advisor/Mentor, Nai-Chung Chang, University of Utah
----------------	---

#### Resident

2013 - 2018	Research Mentor, Elyse Schwab, University of Utah College of Pharmacy.
-------------	--

#### PhD/Doctorate

2014 - Present	Research Mentor, Jessica Le, University of Utah College of Pharmacy.
2018 - Present	Advisor/Mentor, Holly Shoemaker, Department of Population Health Sciences, University of Utah

### **Graduate Student Committees**

2012 - 2013	Member, Cathy Concannon, University of Rochester School of Medicine and Dentistry, Masters Committee. Public Health
2014 - 2017	Member, Yan Cheng, University of Utah, PhD/Doctorate Committee
2014 - 2017	Chair, Rishiraj Deka, University of Utah, PhD/Doctorate Committee
2015 - 2017	Member, Tianze Jiao, University of Utah, PhD/Doctorate Committee
2015 - 2016	Member, Casey Tak, University of Utah, PhD/Doctorate Committee

### **Educational Lectures**

#### Didactic Lectures

2013	<b>Stevens VW.</b> Epidemiology Crash Course for Outcomes Research Fellows. Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT
2013 - Present	<b>Stevens VW.</b> Research Design and Protocol Development. Pharmacy Resident Seminar Series. University of Utah College of Pharmacy, Salt Lake City, UT
2013 - Present	<b>Stevens VW.</b> Collecting and Crunching the Data. Pharmacy Resident Seminar Series, University of Utah College of Pharmacy, Salt Lake City, UT
2014	<b>Stevens VW.</b> Time-Dependent Analyses. Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT

#### Department/Division Conferences

2011	Antibiotics, Acid Suppression, and Risk of <i>Clostridium difficile</i> Infection (CDI), Department of Epidemiology and Biostatistics Noontime Seminar, State University of New York at Albany School of Public Health
2012	<i>Clostridium difficile</i> Infections in Adult and Pediatric Patients, Pediatric Infectious Disease Division Meeting, University of Utah School of Medicine
2013	Pharmacologic Risk Factors for <i>Clostridium difficile</i> Infection, Department of

	Family and Preventive Medicine Research Roundtable, University of Utah School of Medicine
2013	Treatment patterns and outcomes for pediatric patients with <i>Clostridium difficile</i> infection, K-Club, Department of Pediatrics, University of Utah School of Medicine
2014	Treatment Patterns and Outcomes for Pediatric Patients with <i>Clostridium difficile</i> Infection, Pediatric Research in Progress Series, Primary Children's Hospital
2014	Challenges in estimating inpatient costs and length of stay: <i>Clostridium difficile</i> as a case study, Department of Pharmacotherapy Research Roundtable, University of Utah College of Pharmacy
2017	Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and mortality among patients with <i>Clostridium difficile</i> infection. Statistics and Epidemiology Meeting. Division of Epidemiology. University of Utah School of Medicine.

# **PEER-REVIEWED JOURNAL ARTICLES**

1. **Stevens V**, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E (2011). Cumulative antibiotic exposures over time and the risk of *Clostridium difficile* infection. *Clin Infect Dis*, 53(1), 42-8.
2. **Stevens V**, Dumyati G, Brown J, Wijngaarden E (2011). Differential risk of *Clostridium difficile* infection with proton pump inhibitor use by level of antibiotic exposure. *Pharmacoepidemiol Drug Saf*, 20(10), 1035-42.
3. Dumyati G, **Stevens V**, Hannett GE, Thompson AD, Long C, Maccannell D, Limbago B (2012). Community-associated *Clostridium difficile* infections, Monroe County, New York, USA. *Emerg Infect Dis*, 18(3), 392-400.
4. **Stevens V**, Lodise TP, Tsuji B, Stringham M, Butterfield J, Dodds Ashley E, Brown K, Forrest A, Brown J (2012). The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant *Staphylococcus aureus* bacteremia. *Infect Control Hosp Epidemiol*, 33(6), 558-64.
5. **Stevens V**, Concannon C, van Wijngaarden E, McGregor J (2013). Validation of the chronic disease score-infectious disease (CDS-ID) for the prediction of hospital-associated *clostridium difficile* infection (CDI) within a retrospective cohort. *BMC Infect Dis*, 13(1), 150.
6. **Stevens V**, Geiger K, Concannon C, Nelson RE, Brown J, Dumyati G (2014). Inpatient costs, mortality and 30-day re-admission in patients with central-line-associated bloodstream infections. *Clin Microbiol Infect*, 20(5), O318-24.
7. Concannon C, van Wijngaarden E, **Stevens V**, Dumyati G (2014). The effect of multiple concurrent central venous catheters on central line-associated bloodstream infections. *Infect Control Hosp Epidemiol*, 35(9), 1140-6.
8. Nelson RE, **Stevens VW**, Jones M, Samore MH, Rubin MA (2015). Health care-associated methicillin-resistant *Staphylococcus aureus* infections increases the risk of postdischarge mortality. *Am J Infect Control*, 43(1), 38-43.
9. Coon SA, **Stevens VW**, Brown JE, Wolff SE, Wrobel MJ (2015). Comparison of dietary supplement product knowledge and confidence between pharmacists and health food store employees. *J Am Pharm Assoc (2003)*, 55(2), 161-8.
10. Chrastil J, Anderson MB, **Stevens V**, Anand R, Peters CL, Pelt CE (2015). Is Hemoglobin A1c or Perioperative Hyperglycemia Predictive of Periprosthetic Joint Infection or Death Following Primary Total Joint Arthroplasty? *J Arthroplasty*, 30(7), 1197-202.
11. **Stevens VW**, Khader K, Nelson RE, Jones M, Rubin MA, Brown KA, Evans ME, Greene T, Slade E, Samore MH (2015). Excess Length of Stay Attributable to *Clostridium difficile* Infection (CDI) in the Acute Care Setting: A Multistate Model. *Infect Control Hosp Epidemiol*, 36(9), 1024-30.
12. Nelson RE, Nelson SD, Khader K, Perencevich EL, Schweizer ML, Rubin MA, Graves N, Harbarth S, **Stevens VW**, Samore MH (2015). The Magnitude of Time-Dependent Bias in the Estimation of



Excess Length of Stay Attributable to Healthcare-Associated Infections. *Infect Control Hosp Epidemiol*, 36(9), 1089-94.

13. Nelson RE, Samore MH, Jones M, Greene T, **Stevens VW**, Liu CF, Graves N, Evans MF, Rubin MA (2015). Reducing Time-dependent Bias in Estimates of the Attributable Cost of Health Care-associated Methicillin-resistant Staphylococcus aureus Infections: A Comparison of Three Estimation Strategies. *Med Care*, 53(9), 827-34.
14. Jones BE, Jones MM, Huttner B, Stoddard G, Brown KA, **Stevens VW**, Greene T, Sauer B, Madaras-Kelly K, Rubin M, Goetz MB, Samore M (2015). Trends in Antibiotic Use and Nosocomial Pathogens in Hospitalized Veterans With Pneumonia at 128 Medical Centers, 2006-2010. *Clin Infect Dis*, 61(9), 1403-10.
15. Brown K, Samore M, **Stevens V**, Jones M, Mayer J (2015). Imported Disease Pressure and Bulk Antibiotic Use: Novel Predictors of Facility-Level C. Difficile Infection (CDI) Incidence in the United States Veterans Health Administration. *Open Forum Infect Dis*, 2(Suppl 1), 183.
16. Nelson RE, Jones M, Leecaster M, Samore MH, Ray W, Huttner A, Huttner B, Khader K, **Stevens VW**, Gerding D, Schweizer ML, Rubin MA (2016). An Economic Analysis of Strategies to Control Clostridium Difficile Transmission and Infection Using an Agent-Based Simulation Model. *PLoS One*, 11(3), e0152248.
17. **Stevens VW**, Thurm C, Schwab EM, Kronman MP, Gerber JS, Shah SS, Newland JG, Courter J, Parker S, Brogan TV, Hersh AL (2016). Use of Concomitant Antibiotics During Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients: An Observational Cohort Study. *Infect Dis Ther*, 5(1), 45-51.
18. Unni SK, Schauerhamer MB, Deka R, Tyczynski JE, Fernandes AW, **Stevens V**, Brixner DI, Stenehjem DD (2016). BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study. *J Ovarian Res*, 9, 18.
19. Brown KA, Daneman N, **Stevens VW**, Zhang Y, Greene TH, Samore MH, Arora P (2016). Integrating Time-Varying and Ecological Exposures into Multivariate Analyses of Hospital-Acquired Infection Risk Factors: A Review and Demonstration. *Infect Control Hosp Epidemiol*, 37(4), 411-9.
20. Nelson RE, **Stevens VW**, Khader K, Jones M, Samore MH, Evans ME, Douglas Scott R 2nd, Slayton RB, Schweizer ML, Perencevich EL, Rubin MA (2016). Economic Analysis of Veterans Affairs Initiative to Prevent Methicillin-Resistant Staphylococcus aureus Infections. *Am J Prev Med*, 50(5 Suppl 1), S58-S65.
21. Schwab EM, Wilkes J, Korgenski K, Hersh AL, Pavia AT, **Stevens VW** (2016). Risk Factors for Recurrent Clostridium difficile Infection in Pediatric Inpatients. *Hosp Pediatr*, 6(6), 339-44.
22. Brown KA, Jones M, Daneman N, Adler FR, **Stevens V**, Nechodom KE, Goetz MB, Samore MH, Mayer J (2016). Importation, Antibiotics, and Clostridium difficile Infection in Veteran Long-Term Care: A Multilevel Case-Control Study. *Ann Intern Med*, 164(12), 787-94.
23. **Stevens VW**, Nelson RE, Schwab-Daugherty EM, Khader K, Jones MM, Brown KA, Greene T, Croft LD, Neuhauser M, Glassman P, Goetz MB, Samore MH, Rubin MA (2017). Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection. *JAMA Intern Med*, 177(4), 546-553.
24. Nelson RE, Slayton RB, **Stevens VW**, Jones MM, Khader K, Rubin MA, Jernigan JA, Samore MH (2017). Attributable Mortality of Healthcare-Associated Infections Due to Multidrug-Resistant Gram-Negative Bacteria and Methicillin-Resistant Staphylococcus Aureus. *Infect Control Hosp Epidemiol*, 38(7), 848-856.
25. Khadem T, **Stevens V**, Holt K, Hoffmann C, Dumyati G, Brown J (2017). Risk factors for carbapenem-nonsusceptible Pseudomonas aeruginosa: Case-control study. *Diagn Microbiol Infect Dis*, 89(2), 146-150.
26. Brown KA, Daneman N, Jones M, Nechodom K, **Stevens V**, Adler FR, Goetz MB, Mayer J, Samore M (2017). The Drivers of Acute and Long-term Care Clostridium difficile Infection Rates: A

- Retrospective Multilevel Cohort Study of 251 Facilities. *Clin Infect Dis*, 65(8), 1282-1288.
27. Nelson RE, Deka R, Khader K, **Stevens VW**, Schweizer ML, Rubin MA (2017). Dynamic transmission models for economic analysis applied to health care-associated infections: A review of the literature. *Am J Infect Control*, 45(12), 1382-1387.
  28. Cheng Y, Sauer B, Zhang Y, Nickman NA, Jamjian C, **Stevens V**, LaFleur J (2018). Adherence and virologic outcomes among treatment-naïve veteran patients with human immunodeficiency virus type 1 infection. *Medicine (Baltimore)*, 97(2), e9430.
  29. Cheng Y, Nickman NA, Jamjian C, **Stevens V**, Zhang Y, Sauer B, LaFleur J (2018). Predicting poor adherence to antiretroviral therapy among treatment-naïve veterans infected with human immunodeficiency virus. *Medicine (Baltimore)*, 97(2), e9495.
  30. Stenehjem DD, Au T, Sainski AM, Bauer H, Brown K, Lancaster J, **Stevens V**, Brixner DI (2018). Impact of a genetic counseling requirement prior to genetic testing. *BMC Health Serv Res*, 18(1), 165.
  31. **Stevens VW**, Stenehjem DD, Patterson OV, Kamau AWC, Yim YM, Morlock RJ, DuVall SL (2018). Characterization and survival of patients with metastatic basal cell carcinoma in the Department of Veterans Affairs: a retrospective electronic health record review. *Arch Dermatol Res*, 310(6), 505-513.
  32. Louie JM, Lonardo NW, Mone MC, **Stevens VW**, Deka R, Shipley W, Barton RG (2018). Outcomes When Using Adjunct Dexmedetomidine with Propofol Sedation in Mechanically Ventilated Surgical Intensive Care Patients. LID - E93 [pii] LID - 10.3390/pharmacy6030093 [doi]. *Pharmacy (Basel)*, 6(3).
  33. Nelson RE, Jones M, Liu CF, Samore MH, Evans ME, **Stevens VW**, Reese T, Rubin MA (2018). The Impact of Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Infections on Postdischarge Health Care Costs and Utilization across Multiple Health Care Systems. LID - 10.1111/1475-6773.13063 [doi]. (Epub ahead of print) *Health Serv Res*.
  34. Deka R, Bryan CJ, LaFleur J, Oderda G, Atherton A, **Stevens V** (2018). Benzodiazepines, Health Care Utilization, and Suicidal Behavior in Veterans With Posttraumatic Stress Disorder. LID - 10.4088/JCP.17m12038 [doi] LID - 17m12038 [pii]. *J Clin Psychiatry*, 79(6).
  35. Nelson RE, **Stevens VW**, Jones M, Khader K, Schweizer ML, Perencevich EN, Rubin MA, Samore MH (2018). Attributable Cost and Length of Stay Associated with Nosocomial Gram-Negative Bacterial Cultures. LID - e00462-18 [pii] LID - 10.1128/AAC.00462-18 [doi]. *Antimicrob Agents Chemother*, 62(11).
  36. Hong LT, Liou TG, Deka R, King JB, **Stevens V**, Young DC (2018). Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis. *Chest*, 154(5), 1108-1114.
  37. Roland CL, Ye X, **Stevens V**, Oderda GM (2019). The Prevalence and Cost of Medicare Beneficiaries Diagnosed and At Risk for Opioid Abuse, Dependence, and Poisoning. *J Manag Care Spec Pharm*, 25(1), 18-27.

#### **NON PEER-REVIEWED JOURNAL ARTICLES**

1. **Stevens V**, van Wijngaarden E (2013). Proton pump inhibitor use may be associated with an increased risk of Clostridium difficile infection. *Evid Based Med*, 18(5), 193-4.

#### **REVIEW ARTICLES**

1. Rightmier E, **Stevens V**, Brown J (2011). Streptococcus pneumoniae vaccination in older adults. [Review]. *Am J Geriatr Pharmacother*, 9(6), 392-404.
2. Zeitler K, Salvas B, **Stevens V**, Brown J (2012). Aztreonam lysine for inhalation: new formulation of an old antibiotic. [Review]. *Am J Health Syst Pharm*, 69(2), 107-15.
3. Khadem T, **Stevens V** (2013). Therapeutic options for the treatment of postherpetic neuralgia: a

systematic review. [Review]. *J Pain Palliat Care Pharmacother*, 27(3), 268-83.

#### **OTHER (Commentary/Letters/Editorials/Case Reports/Video/Film)**

##### **Editorials**

1. **Stevens V**, Onufrak N, Brown J (2012). Fidaxomicin: balancing evidence and economics. *Am J Health Syst Pharm*, 69(11), 931.

##### **Letters**

1. **Stevens V**, Brown JE (2010). Comment: The relationship between inpatient fluoroquinolone use and *Clostridium difficile*-associated disease [Letter to the editor]. *Ann Pharmacother*, 44(11), 1855-6.
2. Brown KA, Daneman N, **Stevens V**, Greene TH, Arora P (2016). Reply to Wolkewitz: When to Use Cumulative Risk-Based Versus Rate-Based Approaches in the Analysis of Hospital-Acquired Infection Risk Factors? That Depends on the Question [Letter to the editor]. *Infect Control Hosp Epidemiol*, 37(9), 1124-5.

#### **UNPUBLISHED POSTER PRESENTATIONS**

1. **Stevens V**, van Wijngaarden E, Dumyati G (2008). *Impact of Dialysis on Mortality in Healthcare Onset and Community Onset Healthcare-Associated Staphylococcus aureus (HA-MRSA)*. Poster session presented at 18th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America, Orlando, FL.
2. Thompson AD, Bonkosky M, MacCannell D, Dumyati G, Hannett G, **Stevens V**, Soeters M, Gould LH, Long C, Limbago B (2009). *Characterization of Community- and Healthcare-Associated Clostridium difficile from Two States*. Poster session presented at 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA.
3. Dumyati G, Hannett GE, Long C, Thompson A, **Stevens V** (2009). *Clinical Features and Molecular Characterization of Community-Acquired Clostridium difficile Infections (CDI)*. 47th Annual Meeting of the Infectious Disease Society of America. Poster session presented at 47th Annual Meeting of the Infectious Disease Society of America, Philadelphia, PA.
4. Aitken SL, Gibson W, Fominaya C, **Stevens V**, Doloresco F, Brown J (2010). *Equality/inequality of inpatient outcomes for major infectious diseases in the United States*. Poster session presented at American College of Clinical Pharmacy Annual Meeting, Austin, TX.
5. Giroux RL, Smolen AM, Fiebelkorn KD, **Stevens V**, Brown J, Monte S, Wrobel M, Wiegand S, Badgley B (2011). *Assessing the Relationship Between Pharmacy Supplier, Third-Party Prescription Coverage, and Medication Waste*. Poster session presented at American Pharmacists Association Annual Meeting & Exposition, Seattle, WA.
6. Lovria RL, **Stevens V**, Brown J, Heine AM, Johnson K (2011). *Vancomycin-Induced Nephrotoxicity in Pediatric Patients*. Poster session presented at SUNY Buffalo Resident Poster Day, Buffalo, NY.
7. **Stevens V**, van Wijngaarden E (2011). *Ignoring Variability in Timing of Drug Administration Attenuates Hazard Ratios*. Poster session presented at 44th Annual Meeting of the Society for Epidemiologic Research and 3rd North American Congress of Epidemiology, Montreal, Canada.
8. **Stevens V**, Brown JE, Dumyati G (2011). *Proton Pump Inhibitor Use and the Risk of Clostridium difficile by Route of Administration*. Poster session presented at 27th Annual Meeting of the International Society for Pharmacoepidemiology, Chicago, IL.
9. **Stevens V**, Brown JE, Forrest A (2011). *Optimal Vancomycin (V) Concentration Targets for Serious Infections due to Methicillin-Resistant Staphylococcus aureus (MRSA)*. Poster session presented at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL.
10. **Stevens V**, Lodise T, Tsuji B, Hardy D, Dodds-Ashley E, Brown K, Forrest A, Brown JE (2011). *APACHE II Scores for Confounder Control and Prediction of Mortality among ICU and Non-ICU Patients with Staphylococcus aureus Bacteremia*. Poster session presented at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL.

11. Onufrak N, **Stevens V**, Brown K, Brown J (2012). *Vancomycin Dose and Duration of Therapy as Risk Factors for Nephrotoxicity in Adult Patients*. Poster session presented at 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA.
12. **Stevens V**, Onufrak N, Brown K, Brown J (2012). *Average 24-hour Area Under the Vancomycin (V) Serum Concentration-Time Curve (AUC), Degree of Nephrotoxicity (NT), and Need for Dialysis*. Poster session presented at 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA.
13. Onufrak N, **Stevens V**, Forrest A, Brown J (2012). *Association between Vancomycin AUC24/MIC and Attainment and Time-to-Clinical Cure among Patients with Enterococcal Bloodstream Infections*. Poster session presented at Midyear Meeting of the American Society of Health-System Pharmacists, Las Vegas, NV.
14. Coon S, **Stevens V**, Brown J, Wrobel M (2012). *Comparison of product knowledge and confidence between pharmacists and health food store employees*. Poster session presented at Midyear Meeting of the American Society of Health-System Pharmacists, Las Vegas, NV.
15. Bossard W, Brown J, Albanese N, Slazak E, **Stevens V** (2012). *Anti-diabetic Agents and the Risk of Clostridium Difficile Infections*. Poster session presented at Midyear Meeting of the American Society of Health-System Pharmacists, Las Vegas, NV.
16. Concannon C, van Wijngaarden E, **Stevens V**, Thevenet-Morrison K, Dumyati G (2013). *The Effect of Multiple Concurrent Central Venous Catheters on Central Line Associated Bloodstream Infections*. Poster session presented at 40th Annual Conference of the Association for Professionals in Infection Control, Ft. Lauderdale, FL.
17. **Stevens V**, Yoo M, Brown J (2013). *Cost and Length of Stay Associated with Vancomycin-Induced Nephrotoxicity*. Poster session presented at 16th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Dublin, Ireland.
18. Liu C, **Stevens V**, Murnin K, Jennings B (2014). *Demographics and Clinical Characteristics of Patients Hospitalized with Prescription Opioid-Related Overdose*. Poster session presented at American Pharmacists Association Annual Meeting & Exposition, Orlando, FL.
19. Miles M, Gunning K, **Stevens V**, Jennings B (2014). *Transitions of Care in Heart Failure: Identifying Patients for Intervention*. Poster session presented at American Pharmacists Association Annual Meeting & Exposition, Orlando, FL.
20. **Stevens V**, Korgenski EK, Wilkes J, Pavia AT (2014). *Patterns and Outcomes of Treatment in Pediatric Patients with Clostridium difficile Infection*. Poster session presented at Pediatric Academic Societies Meeting, Vancouver, BC, Canada.
21. Hansen A, **Stevens VW**, Brailsford M, Farrell T, Gunning K (2014). *Evaluation of aspirin prescribing practices for primary prevention in women over the age of 65 at an academic family practice clinic*. Poster session presented at American Association of Colleges of Pharmacy Annual Meeting, Grapevine, TX.
22. Khader K, Mohanty A, Nelson RE, Jones M, **Stevens VW**, Huskins CW, Samore MH (2014). *Excess Length of Stay due to Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci Infections at ICUs across the United States*. Poster session presented at IDWeek 2014, Philadelphia, PA.
23. Nelson RE, **Stevens VW**, Jones M, Samore MH, Rubin MA (2014). *Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Infections Increase the Risk of Post-Discharge Mortality*. Poster session presented at IDWeek 2014, Philadelphia, PA.
24. **Stevens VW**, Thurm C, Kronman MP, Gerber JS, Shah SS, Newland JG, Courter J, Parker S, Brogan TV, Hersh AL (2014). *Use of Concomitant Antibiotics during Treatment for Clostridium difficile Infection (CDI) in Pediatric Inpatients*. Poster session presented at IDWeek 2014, Philadelphia, PA.
25. **Stevens VW**, Khader K, Nelson RE, Jones M, Rubin MA, Samore MH (2014). *Excess Length of Stay Attributable to Clostridium difficile Infection (CDI) in the Acute Care Setting: A Multi-State*

- Model*. Poster session presented at IDWeek 2014, Philadelphia, PA.
26. Hong LT, Young DC, Zobell JT, Bhakta Z, **Stevens VW**, King J, Carveth H, Liou TG (2014). *Pharmacokinetics of continuous infusion beta-lactams and tobramycin in the treatment of acute pulmonary exacerbations in adult cystic fibrosis patients*. Poster session presented at University HealthSystem Consortium Meeting.
  27. Pelt C, Chrastil J, Anderson M, **Stevens V**, Anand R, Duvall S, Peters C (2015). *Is Hemoglobin A1c Predictive of Periprosthetic Joint Infection or Death Following Primary Total Joint Replacement?* Poster session presented at Annual Meeting of the American Academy of Orthopaedic Surgeons, Las Vegas, NV.
  28. Van Wagoner E, Nickman N, Moorman K, **Stevens VW**, Tak C, Jennings B (2015). *Assessing employee perception of patient safety culture within a university-based health system's community pharmacies using the AHRQ community pharmacy survey on patient safety culture*. Poster session presented at American Pharmacists Association Annual Meeting & Exposition, San Diego, CA.
  29. Brown KA, Jones MM, Adler F, Leecaster M, Nechodom K, **Stevens VW**, Samore MH, Mayer J (2015). *The determinants of C. difficile infection in long-term care facilities: a portrait of patient- and facility-level factors across 90 care regions in the Veteran Affairs Health System*. Poster session presented at Health Services Research and Development Conference, Philadelphia, PA.
  30. Leecaster M, Khader K, Nelson RE, Ray W, **Stevens VW**, Toth D, Rubin MA (2015). *Assessment of Hand Hygiene Adherence in Prevention of Clostridium difficile Acquisition*. Poster session presented at Health Services Research and Development, Philadelphia, PA.
  31. Nelson RE, Samore MH, Khader K, Jones MM, **Stevens VW**, Schweizer M, Perencevich E, Rubin MA (2015). *Economic analysis of Veterans Affairs initiative to prevent methicillin-resistant staphylococcus aureas infections*. Poster session presented at Health Services Research and Development Conference, Philadelphia, PA.
  32. Jones MM, Khader K, Nelson RE, **Stevens VW**, Samore MH, Mayer J, Rubin MA (2015). *Effects of initial anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics on nosocomial MRSA acquisition and clinical cultures*. Poster session presented at IDWeek 2015, San Diego, CA.
  33. Jones MM, Nelson RE, Khader K, Mayer J, **Stevens VW**, Samore MH, Rubin MA (2015). *Lower methicillin-resistant Staphylococcus aureus (MRSA) acquisition and nosocomial cultures while on anti-MRSA antibiotics*. Poster session presented at IDWeek 2015, San Diego, CA.
  34. Nelson RE, Slayton RB, **Stevens VW**, Jones M, Khader K, Rubin MA, Jernigan J, Samore MH (2015). *Healthcare-associated infections due to gram negative bacteria increase the risk of mortality*. Poster session presented at IDWeek 2015, San Diego, CA.
  35. Khadem T, **Stevens VW**, Holt K, Hoffman C, Dumyati G, Brown JE (2015). *Risk Factors for Carbapenem-non-susceptible Pseudomonas aeruginosa Infections Compared to Susceptible Counterparts: a Case-Control Study*. Poster session presented at IDWeek 2015, San Diego, CA.
  36. Roland K, **Stevens VW**, Oderda G (2015). *Prevalence and direct costs of opioid abuse in medicare beneficiaries*. Poster session presented at Academy of Managed Care Pharmacy Nexus, Orlando, FL.
  37. **Stevens VW**, Khader K, Brown KA, Nelson RE, Leecaster, M, Ray W, Toth D, Rubin MA (August 2016). *Intravenous vancomycin and the risk of Clostridium difficile Infection*. Poster session presented at 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland.
  38. **Stevens VW**, Khader K, Nelson RE, Toth D, Leecaster M, Samore MH, Rubin MA (October 2016). *Variation in and predictors of oral vancomycin treatment among patients with Clostridium difficile infection (CDI)*. Poster session presented at ID Week 2016, New Orleans, LA, USA.

## **ORAL PRESENTATIONS**

### **Meeting Presentations (Not Published Abstracts and Not Unpublished Posters)**

#### **International**

- 2010 **Stevens V**, Dumyati G, Fisher SG, Fine LS, van Wijngaarden E. Time-Varying Antibiotic Exposures and Risk of *Clostridium difficile* Infection (CDI). 26th Annual Meeting of the International Society for Pharmacoepidemiology, Brighton, England
- 2011 **Stevens V**, Dumyati G, Brown JE, van Wijngaarden E. Differential Risk of *Clostridium difficile* Infection with Proton Pump Inhibitor Use by Level of Antibiotic Exposure. 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy, Milan, Italy
- 2015 **Stevens VW**, Nelson RE, Khader K, Jones M, Brown KA, Samore MH, Rubin M. Recurrence and mortality following treatment for *Clostridium difficile* infection (CDI) with metronidazole or vancomycin. International Conference on Prevention and Infection Control (ICPIC), Geneva, Switzerland
- 2018 **Stevens VW**, Khader K, Nelson RE, Jones MM, Timbrook T, Samore MH, Rubin MA. Use of oral vancomycin for *Clostridium difficile* Infection (CDI) and the risk of vancomycin-resistant Enterococci (VRE). Presented at the European Congress on Clinical Microbiology and Infectious Diseases. Madrid, Spain.
- 2019 **Stevens VW**, Khader K, Echevarria K, Samore MH. Trends in fluoroquinolone and cephalosporin prescribing and *Clostridioides difficile* infections in acute and long-term care facilities in the US Department of Veterans Affairs Health System. Presented at the European Congress on Clinical Microbiology and Infectious Diseases. Amsterdam, Netherlands.

#### National

- 2011 **Stevens V**, Brown JE, Forrest A. Optimal Vancomycin (V) Concentration Targets for Serious Infections due to Methicillin-Resistant *Staphylococcus aureus* (MRSA). Annual Meeting of the International Society for Anti-Infective Pharmacology, Chicago, IL
- 2014 **Stevens V**. Longitudinal Epidemiology of *Clostridium difficile* Infections among Patients in the Veterans Affairs Health System. IDWeek 2014, Philadelphia, PA
- 2015 **Stevens V**. Evaluation of Existing Clinical Prediction Rules to Identify Patients at Risk of Recurrent *Clostridium difficile* Infection (rCDI) using Electronic Health Record (EHR) Data from the Veterans Affairs Health System. IDWeek, San Diego, CA

#### **Invited/Visiting Professor Presentations**

##### National

- 2016 - 2018 **Stevens V**. Defining the Research Question: Finding the right answers starts with finding the right questions. Antimicrobial Stewardship Research Workshop. Society for Healthcare Epidemiology of America. San Diego, California (2016), Chicago, Illinois (2017), and Baltimore, Maryland (2018).
- 2016 - 2018 **Stevens V**. Using Health Economics to Evaluate Antimicrobial Stewardship Activities. Antimicrobial Stewardship Research Workshop. Society for Healthcare Epidemiology of America. San Diego, California (2016), Chicago, Illinois (2017), and Baltimore, Maryland (2018)
- 2018 **Stevens V**. What Not to Do: Faux Pas in Statistical Analysis. Antimicrobial Stewardship Research Workshop. Society for Healthcare Epidemiology of America. Baltimore, Maryland.
- 2018 **Stevens V**. Big Science: A multi-disciplinary approach to reducing the impact of *Clostridium difficile* infections in the VA healthcare system. Epidemiology Seminar, Department of Population Health Sciences, University of Rochester School of Medicine and Dentistry

2018 **Stevens V.** Keynote speaker, University of Rochester School of Medicine and Dentistry Graduate School Interview Weekend.

Local/Regional

2011 **Stevens V.** Research Design. Grantsmanship Workshop, St. John Fisher College Wegmans School of Pharmacy, Rochester, NY

2011 **Stevens V.** Clostridium difficile: Epidemiology and Treatment of a Difficult Disease. Annual Meeting of the New York State Chapter of the American College of Clinical Pharmacy, D'Youville College School of Pharmacy, Buffalo, NY

2012 **Stevens V.** Pharmacologic Risk Factors for *Clostridium difficile* Infection (CDI). Salt Lake City Veterans Affairs Informatics, Decision Enhancement, and Surveillance (IDEAS) Center, Salt Lake City, UT

2014 **Stevens V.** Management of Pediatric *Clostridium difficile* Infection. Issues in Pediatric Care Nursing Conference, Intermountain Healthcare, Salt Lake City, UT